SYNAPS Dx Completes $10 Million Series A Investment, Accelerates Commercialization of DISCERN: First Minimally Invasive Test for Accurate Diagnosis of Alzheimer’s Disease
Home » SYNAPS Dx Completes $10 Million Series A Investment, Accelerates Commercialization of DISCERN: First Minimally Invasive Test for Accurate Diagnosis of Alzheimer’s Disease
SYNAPS Dx Completes $10 Million Series A Investment, Accelerates Commercialization of DISCERN: First Minimally Invasive Test for Accurate Diagnosis of Alzheimer’s Disease2021-10-122021-10-14http://redpeppermergers.com/wp-content/uploads/rpm-white-red-1.pngRedPepper Mergershttp://redpeppermergers.com/wp-content/uploads/rpm-white-red-1.png200px200px
VIEW ARTICLE If you would like to know more regarding the topic in this blog post, please do not hesitate to contact us.